 REDWOOD CITY, Calif., Feb. 10, 2021 GLOBE NEWSWIRE -- Adverum Biotechnologies, Inc. Nasdaq: ADVM, a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal IVT injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration AMD. These data were previously presented as part of a corporate update on Saturday, November 14, 2020. 